Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
$757K Buy
12,490
+5,663
+83% +$344K 0.18% 88
2016
Q4
$383K Buy
6,827
+1,101
+19% +$64.4K 0.09% 102
2016
Q3
$341K Hold
5,726
0.1% 92
2016
Q2
$315K Buy
5,726
+1,415
+33% +$75.3K 0.08% 107
2016
Q1
$218K Hold
4,311
0.06% 115
2015
Q4
$217K Buy
4,311
+70
+2% +$3.53K 0.06% 116
2015
Q3
$200K Sell
4,241
-105
-2% -$5.58K 0.06% 117
2015
Q2
$236K Buy
4,346
+65
+2% +$3.65K 0.06% 111
2015
Q1
$235K Sell
4,281
-105
-2% -$5.95K 0.06% 123
2014
Q4
$238K Hold
4,386
0.06% 118
2014
Q3
$248K Buy
4,386
+37
+0.9% +$2.08K 0.06% 118
2014
Q2
$240K Hold
4,349
0.06% 107
2014
Q1
$236K Buy
4,349
+97
+2% +$5.02K 0.06% 105
2013
Q4
$203K Buy
+4,252
New +$194K 0.05% 115

Other funds holding MRK

Agran Libbie's MRK Position: Q1 2017 in Review

Agran Libbie increased its Merck (MRK) stake by 83% in Q1 2017, buying an estimated $344K and bringing the position to 12,490 shares worth $757K. The position accounts for 0.18% of the portfolio, ranked #88.

Agran Libbie first reported a position in MRK in Q4 2013 and has held it in 14 quarters since. 1,941 funds tracked by Wall St. Rank hold MRK as of Q1 2017.

  • Agran Libbie held 12,490 shares of Merck worth $757K as of Q1 2017.
  • Agran Libbie bought 5,663 Merck shares in Q1 2017, an estimated $344K.
  • Merck made up 0.18% of Agran Libbie's portfolio in Q1 2017, its #88 holding.
  • Agran Libbie first reported a position in Merck in Q4 2013 and has held it in 14 quarters since.
  • 1,941 funds tracked by Wall St. Rank held Merck as of Q1 2017.

Based on Agran Libbie's 13F filing for Q1 2017, filed 27 Apr 2017.